Vincristine sulfate

Catalog No.S1241

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Price Stock Quantity  
USD 90 In stock
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Vincristine sulfate Chemical Structure

Vincristine sulfate Chemical Structure
Molecular Weight: 923.04

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Microtubule Associated Inhibitors
    Compare Microtubule Associated Products
  • Research Area

Product Description

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets Microtubules [1]
(Cell-free assay)
IC50 32 μM
In vitro Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HepG2.2.15M1jjOGNmdGxiVnnhZoltcXS7IFHzd4F6M37relAuOC53IN88US=>MUKyOEBpMYXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?NFe4fIQzPTZ4M{e2PS=>
HepG2-HBV1.1NEDZ[GJCeG:ydH;zbZMhSXO|YYm=NX;iXHg{OC1yLkWg{txOM3jzclI1KGh?M{\Id4lv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=MVqyOVY3Ozd4OR?=
HepG2.2.15NX\2U2o5TnWwY4Tpc44hSXO|YYm=NVXsT4t1OC5zIN88US=>M{LhNVI1KGh?Ml\4dJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;uM2jzUFI2PjZ|N{[5
HepG2-HBV1.1M2ftfWZ2dmO2aX;uJGF{e2G7Mn7HNE4yKM7:TR?=M3HuWFI1KGh?NFr2VXlxem:vb4Tld{Bp\XCjdHn0bZMhSiC4aYL1d{Bxem:2ZXnuJIV5eHKnc4Ppc44>M3;VO|I2PjZ|N{[5
HepG2-HBV1.1NE\2[mhHfW6ldHnvckBCe3OjeR?=MXuwMlEh|ryPNYnie2dvPDhiaB?=NIf2dIFxem:vb4Tld{Bk\WyuIHX4Z5JmfGmxbjDv[kBp\XCjdHn0bZMhSiC4aYL1d{BvfWOuZX;jZZB{cWS|IHnud5Rm[WRib3[gbIVx[XSrdHnzJGIhfmm{dYOgSIFv\SCyYYL0bYNt\XN?MoflNlU3PjN5Nkm=
HepG2-HBV1.1MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnUd5p{OC5zIN88US=>M2i2Z|EuPSCmNW\FU|lZcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=>MYeyOVY3Ozd4OR?=
HepG2-HBV1.1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHMNE4yKM7:TR?=MnjnNU02KGR?M{HSW4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm=NIDqeGYzPTZ4M{e2PS=>
HepG2-HBV1.1MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXmwMlEh|ryPMVuxNk04OiCqNH\lZmdqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>MViyOVY3Ozd4OR?=
HepG2-HBV1.1MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYiwMlEh|ryPNGnQS3UyOi15MjDoNG\Kbo5qdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>M1Pn[lI2PjZ|N{[5
RajiMlzrSpVv[3Srb36gRZN{[Xl?NF\LVJQxNjYEoN88US=>NWLnZXJqPzJiaB?=NW\LcFVE[WKxbHnzbIV{KGG3dH;wbIFogcLiNHLZbIIzPTR2NkO3Oy=>
SK-MEL-28 MVXGeY5kfGmxbjDBd5NigQ>?MVezNEBvVQ>?MX62JIg>NFXGfWJqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?=NVG3PYx3OjV|MUOwNVA>
H157NWnMbVZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHsRm9KSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?=MWWyOVI2PzlzMR?=
JurkatMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfaWWMyNTNibl2=MmjIOFjDqGh?MnjvSG1UVw>?NIXvNXpl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6MXyyOVE2PjF2Nh?=
CEMMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofONU0{KG6PNWfMdph[PDkEoHi=MVXEUXNQNEPQ[Itl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6NX7WcXI{OjVzNU[xOFY>
P12NHfHU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfMO3hTOS1|IH7NNHvMWoo1QMLiaB?=M4LwSGROW09?NHPyVHZl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6MUKyOVE2PjF2Nh?=
KBMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DjT2lEPTB;MD6wNFQ6KMLzIECuNFAxOSEQvF2=M3rlclI2ODV6NUK2
KBv200 (ABCB1)MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3qfWJWUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=>NV;nZpZLOjVyNUi1NlY>
SUDHL6 M3PVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH[zOWQy6oDLzszNM3LvRVQ5Nzd{IHi=M3rqPIlvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>M2Drc|I1QTZzNkC0
SUDHL6 NXTme4g3TnWwY4Tpc44hSXO|YYm=MX:x5qCK|ryPM2rITVczKGh?MlXMbY5lfWOnczDzbYdvcW[rY3HueEBieG:ydH;0bYMhdW:{cHjvcI9ogSClaHHu[4V{KGOxdILld5Rm\CC5aYToJGJEVDFzQTDzbXJPSQ>?MlnYNlQ6PjF4MES=
HCT-116MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rsWGdKPTB;NTDuUS=>MVmyOFkzPzh3Nx?=
SKNBe2CM{P4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\TemlEPTB;M{KuPOKyPC5yIH7NMnTCNlQ6OjF7MkC=
IGNR91MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTJ2LkRCtVEvPyCwTR?=M4HhcFI1QTJzOUKw
SKNASMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrUbY5DUUN3ME2xMlXDuTBwMjDuUS=>M1vJfVI1QTJzOUKw
LAN1NVPuZlBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTqO|ZKSzVyPUKuN:KyOC5{IH7NM4\4clI1QTJzOUKw
SHSY5YNWLpOYs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRThwMtMxNE43KG6PMoGxNlQ6OjF7MkC=
A549-WTMoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTF7LkSzO{DDuSByLkW5OEAhdk1?NGf5c|MzPDh3OEiyOy=>
A549-RMnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1?NXjNV|g5OjR6NUi4Nlc>
MCF-7-WTNYLZO3NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;3bY9CUUN3ME2xO{44PTJiwsGgNE4zOThiIH7NNV7V[3hzOjR6NUi4Nlc>
MCF-7-RNU\XUnhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljjTWM2OD13LkWzPUDDuSByLkG0OEAhdk1?NFfoPGozPDh3OEiyOy=>
A549-RM4HQ[GN6fG:2b4jpZ4l1gSCDc4PhfS=>MWXJR|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>?M1mxbVI1QDV6OEK3
MCF-7-RM1XNbWN6fG:2b4jpZ4l1gSCDc4PhfS=>M{TTb2lEPTB;NT61N|khyrFiMD6xOFQhdk1?NYLqXYtZOjR6NUi4Nlc>
SW620MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;VTWM2OD15LkiwJOKyKDBwMEigcm0>NUXzepR2OjR5Mk[3N|k>
SW620/AD300NXfnd4JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPITWM2OD17MEmuOlAhyrFiOD65NUBvVQ>?NHT3Wo4zPDd{NkezPS=>
HEK293/pcDNA3.1NHnDfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nQfGlEPTB;MT60OUDDuSByLkKwJI5ONXjjUVQ1OjR5Mk[3N|k>
HEK293/ABCC1NVj3NndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHFeIRSUUN3ME2xPU4zQSEEsTCyMlA5KG6PM2\BTVI1PzJ4N{O5
TCCMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfSOG8zPCCqMW\JR|UxRTdyIH7NNGKwXmozPDdzNkm0OC=>
TCCNFfs[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfIU|E1QCCqMoO5TWM2OD13MDDuUS=>MmTmNlQ4OTZ7NES=
HepG2/ADMMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nUcmlEPTB;Mj63PFY{yrFyLkKzO|Eh|ryPNHrWb4MzPDdyNEW1Oi=>
HepG2Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\2OmlEPTB;MD6wNVE2yrFyLkCwNVch|ryPM4PzblI1PzB2NUW2
MCF-7/ADRNHz0VGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWW4cmw6UUN3ME20MlQ5OjcEsUCuNlA4OCEQvF2=Mnn1NlQ4ODR3NU[=
MCF-7M{XTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXBZW5OUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2=NESyW4YzPDdyNEW1Oi=>
A-172 M{nQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWiwMlHDqM7:TR?=MUmyOE84OiCqNV3SVGFtcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>?MkLyNlQ2OzB{M{W=
U-251MGNHWzNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXqwMlHDqM7:TR?=Mlu0NlQwPzJiaB?=MmrqbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>MkHRNlQ2OzB{M{W=
DLD-1NUPrRm9pTnWwY4Tpc44hSXO|YYm=NHjIWJkyODBibl2=NV[2Z4tkPDhiaB?=MnHCdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKhMVGyOFQxOzR3Mx?=
CCD18CoMX;GeY5kfGmxbjDBd5NigQ>?NFTJVW0yODBibl2=MnGzOFghcA>?MXXwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA>NGLHbnUzPDRyM{S1Ny=>
DLD-1M2jMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYD4XGZiOC1zMECwJI5OMWS0PEBpMXPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5NX24U5BJOjR2MEO0OVM>
CCD18CoMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn22NE0yODByIH7NMlnCOFghcA>?NF\lfolqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6NYnublVDOjR2MEO0OVM>
HepG2NUnlcHczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4D1[VI1KGh?NHHGOplKSzVyPUWyMlXjiIoQvF2=NXTIOYNpOjR|NEG2PFg>
HEK293/pcDNA3.1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXxXGg4UUN3ME2wMlAxPMLzMD6wNFA{KM7:TR?=M4K3ZlI1Ojh2N{iz
HEK293/MRP1NHnPUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTBwMEW1xtExNjBzMkCg{txONGfs[JkzPDJ6NEe4Ny=>
RamosM1;1bmFxd3C2b4Ppd{BCe3OjeR?=M4j2b|LjiIoQvF2=NVS1RWlzPDhiaB?=M{PMbIlv\HWlZYOgN|QvPiYEsUGuPVImKGGyb4D0c5Nqew>?MYKyOFI2PjR7MR?=
NCI-H1299/pcDNA3MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>M3jVeVAuOjBibl2=NETnPJI6PiCqNULHfJRicW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=M1ewN|I1OTd5MEGy
H1299/ICAM-3MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NWqzboR5OC1{MDDuUS=>NET0TWQ6PiCqMoribY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?NWjOZVJ{OjRzN{ewNVI>
NCI-H1299/pcDNA3Ml30SpVv[3Srb36gRZN{[Xl?Mor6NU82NzFyL{KwxsBvVQ>?MV65OkBpNXzsTHVpcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>?NIrHR5QzPDF5N{CxNi=>
H1299/ICAM-3MWPGeY5kfGmxbjDBd5NigQ>?NGDx[XIyNzVxMUCvNlDDqG6PNYDJ[W1wQTZiaB?=NXHMdZdrcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>?NYnYcGNROjRzN{ewNVI>
W1NHX6[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTRTWM2OD1yLkCwN|Ih|ryPMmrYNlQyPDBzN{[=
W1VRMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vVd2lEPTB;MD6wOVYh|ryPM1TUXlI1OTRyMUe2
K562M2X3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlf6TWM2OD1yLkCzNkDDuSByLkCwNUAh|ryPNGHJS|EzPDF|NUmzOy=>
K562/ADRMlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTNwMk[xJOKyKDBwNEGyJO69VQ>?M37lV|I1OTN3OUO3
K562M2HWfWFxd3C2b4Ppd{BCe3OjeR?=M4LHTFAvOyEQvF2=MYKyOEBpNHPNbXpqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7MkPzNlQyOzV7M{e=
K562/ADRM3\nWGFxd3C2b4Ppd{BCe3OjeR?=MYSzJO69VQ>?M4XkXVI1KGh?MnvwbY5lfWOnczDhdI9xfG:|aYO=M2rRXVI1OTN3OUO3
A549MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHOUnpQUUN3ME2wMlExKMLzIECuNFMh|ryPMojzNlM6PzFyN{W=
K562NHT6N5RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?NEPafVc{Njd34pETOlDDqG6PMYS3NuKhcMLiMV3pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6NF;6WZozOzh5N{KyNy=>
lucenaNX3ISIJZS2WubDDWbYFjcWyrdImgRZN{[Xl?NEjkNJA{Njd34pETOlDDqG6PM1LWOlczyqCqwrC=NX;CeI1Edm9iZX\m[YN1NGfsNZUzOzh5N{KyNy=>
FEPSNVXQXXZkS2WubDDWbYFjcWyrdImgRZN{[Xl?Ml\SN{44PeLCk{[wxsBvVQ>?MoXyO|LDqGkEoB?=NGXjSGlvdyCnZn\lZ5Q>MoTCNlM5Pzd{MkO=
A2780NUS5UZN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTNwNTDtUS=>M1;BfVI{QDJ7MkCz
ACHNNHHrSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnNTWM2ODxyLkGgcW0>MWKyN|gzQTJyMx?=
U-937NEe2dGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoL5TWM2ODx|NDDuUS=>M{XpWlI{QDJ7MkCz
JurkatM{XsdWFxd3C2b4Ppd{BCe3OjeR?=MUC1xsDPxGdxbX|CpC=>MYeyOEBpMUHpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6MWmyN|gyODRyOR?=
JurkatNYCyeJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fWOVXDqM7:Zz;tcOKhNEPyUY8zPCCqMo\rZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOnMkHqNlM5OTB2MEm=
Hep-2M4m2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUWwVJF1UUN3ME2wMlA1yrFyLkCxJO69VQ>?MkLpNlM4QDB2MkS=
Hep-2/vM2jCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfFPFFnUUN3ME2xMljDuTBwMkCg{txONUHxOVVmOjN5OEC0NlQ>
SGC-7901M1K0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWSwMVExKM7:Zz;tcC=>M4XjelI1NzR6L{eyJIg>M3i2R4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>NFO2SHkzOzd2M{W3Ni=>
SGC-7901/VCRMkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvYV2kxNTFyIN88[{9udA>?M{XyZVI1NzR6L{eyJIg>M4\P[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>NFvvR2szOzd2M{W3Ni=>
SGC-7901M2\F[WFxd3C2b4Ppd{BCe3OjeR?=MVrpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6M4C3[lI{PzR|NUey
SGC-7901/VCRNVnG[HZXSXCxcITvd4l{KEG|c3H5NITBW2lqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7NHTifmIzOzd2M{W3Ni=>
KB-3-1M{Xq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fRRWlEPTB;MT62OkDDuSByLkG2NkDPxE1?NUfRN3psOjN4N{O0OFU>
KB-C2M2HXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3n6NGlEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2=MYeyN|Y4OzR2NR?=
KB-3-1M{TEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTxRphLUUN3ME2xMlI3KMLzIECuNFI4KM7:TR?=MVSyN|Y4OzR2NR?=
KB-V1NW\pUmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLkTWM2OD1{MEiuPFUhyrFiMkCuOEDPxE1?MX2yN|Y4OzR2NR?=
HEK293/pcDNA3.1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XJdWlEPTB;MkSuNUDDuSByLkKwOEDPxE1?NEPqSYozOzZ5M{S0OS=>
HEK293/ABCB1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLLV4NKSzVyPUO1NVIvQCEEsTCzO|gvOzlzIN88US=>NHr4VJQzOzZ5M{S0OS=>
A549/EGFP MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TLTFAvODFvMUCwNEDPxE1?MXXJR|UxRTh4LkegxtEhOjlwMTFOwG0>M37jOlI{PjN2Mkiy
A549/SlugNX;hW|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XONlAvODFvMUCwNEDPxE1?NXTROHNYUUN3ME25MlchyrFiMz6xJO69VQ>?NY[4VG5oOjN4M{SyPFI>
JFCR39 NF\SfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLmO|czOSEEtV2=MXuyOEBpNVm5S4NWTE2VTx?=NGPMNZZu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy|MYOyN|U6QDJ5Nh?=
A549MWrGeY5kfGmxbjDBd5NigQ>?NIL6c5QyODBibl2=MoKwNVYhcA>?M2rRe2ROW09?M2XrN4xm[WS|IITvJIEhdG:|czDv[kBucWO{b4T1ZpVt\XN?MVGyN|U6QDJ5Nh?=
SGC7901MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;LTWM2OD1zLkK25qCKyrIkgJmwMlEyKM7:Zz;tcC=>NG\rVmEzOzV4NES4Ni=>
SGC7901/LV-NCNX;tNnlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrCTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=>NETqc5UzOzV4NES4Ni=>
SGC7901/LV-SGO1NInhbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TQe2lEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw>NIfnd|QzOzV4NES4Ni=>
SGC7901/VCRNV\4eFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDLTWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw>Ml;5NlM2PjR2OEK=
SGC7901/VCR-NCMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDNNYpKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>?MnXINlM2PjR2OEK=
SGC7901/VCR-si-SGO1NV36S2JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\NcYxKSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41tNFzrSHQzOzV4NES4Ni=>
SGC7901/ADRNUjReVlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\MPWlEPTB;Nz64OgKBkcLz4pEJNE43PCEQvHevcYw>MYKyN|U3PDR6Mh?=
SGC7901/ADR-NCMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG3TWZKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41tNU\Y[5ZwOjN3NkS0PFI>
SGC7901/ADR-si-SGO1NVjUfHRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\Te2N2UUN3ME2zMlQ36oDLwsJihKkxNjJ7IN88[{9udA>?M2X0WlI{PTZ2NEiy
SH-SY5Y MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIX0PJMxNjByMT2xNEDPxE1?NX7LfW5POjRiaB?=NWfTXmpwUUN3ME2wMlEyO8LzMD6wNVIh|ryPMkjTNlMyOjlyNkW=
SH-SY5Y NV3JeIpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzy[3AxNjByMT2xNEDPxE1?MXm0PEBpMnO2TWM2OD1yLkC3POKyOC5yMEmg{txOMWCyN|EzQTB4NR?=
SH-SY5Y NFXreVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXG5OZRyOC5yMEGtNVAh|ryPMWe3NkBpNH7IU5lKSzVyPUCuNFUyyrFyLkCwPEDPxE1?MmPONlMyOjlyNkW=
SH-SY5YM3n2U2Fxd3C2b4Ppd{BCe3OjeR?=NIrDUIUxNjFizszNNInYdmoxNTJ2IHi=MkjibY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W=MYOyN|EzQTB4NR?=
SH-SY5YMkPURZBweHSxc3nzJGF{e2G7NV3abHBFOC5zIN88US=>M4TFdlAuOjRiaB?=M4\PS4lv\HWlZYOgcYl1d3SrYzDhdpJme3UEoB?=NFPRe4IzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]
Features

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines B16 melanoma cell
Concentrations 10 nM
Incubation Time 3 days
Method Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.

Animal Study: [6]

Animal Models Human rhabdomyosarcoma xenografts Rh12
Formulation Water solutioin
Dosages 3 mg/kg
Administration A single i.p. administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Jordan MA, et al. Cancer Res, 1985, 45(6), 2741-2747.

[2] Gidding CE. Crit Rev Oncol Hematol, 1999, 29(3), 267-287.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02724579 Not yet recruiting Untreated Childhood Medulloblastoma Childrens Oncology Group|National Cancer Institute (NCI) October 2016 Phase 2
NCT02703272 Not yet recruiting Lymphoma, Non-Hodgkin Janssen Research & Development, LLC October 2016 Phase 3
NCT01775475 Not yet recruiting AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Imm  ...more AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma AIDS Malignancy Consortium|National Cancer Institute (NCI  ...more AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation September 2016 Phase 2
NCT02257242 Not yet recruiting Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Mantle-Cell|Lymphoma, Small-Cell|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell, Marginal Zone Adam Olszewski|Spectrum Pharmaceuticals, Inc|Rhode Island  ...more Adam Olszewski|Spectrum Pharmaceuticals, Inc|Rhode Island Hospital|The Miriam Hospital|Brown University September 2016 Phase 1
NCT02723994 Not yet recruiting B-cell Acute Lymphoblastic Leukemia Incyte Corporation|Childrens Oncology Group August 2016 Phase 2

view more

Chemical Information

Download Vincristine sulfate SDF
Molecular Weight (MW) 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms Leurocristine
Solubility (25°C) * In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo Saline 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name  22-​oxo-vincaleukoblastine, sulfate (1:1)

Customer Product Validation(2)


Click to enlarge
Rating
Source Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck
Method [methyl-3H]thymidine Assays
Cell Lines Patched mutant tumor cells
Concentrations 0-10 mmol/L
Incubation Time 48 h
Results Addition of BI-2536 dramatically increased the sensitivity of the tumor cells to vincristine; while the IC50 value for vincristine alone was approximately 5 nMol/L, the IC50 value for vincristine combined with BI-2536 was approximately 0.1 nMol/L.

Click to enlarge
Rating
Source Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck
Method Cell Viability Assay
Cell Lines HXO-RB44 cells
Concentrations 0.1-100 nM
Incubation Time 96 h
Results Compared with the treatment with SG600 or VCR alone, the survival rates of RB cells decreased markedly when treated with the combination of SG600 and VCR in the process with increasing dose. Cytotoxicity of VCR in the HXO-RB44 cell line was also evaluated by IC50 values (Figure B).

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Microtubule Associated Products

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • Paclitaxel

    Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

  • Docetaxel

    Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Nocodazole

    Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively.

  • Vinblastine

    Vinblastine inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

  • Cabazitaxel

    Cabazitaxel is a semi-synthetic derivative of a natural taxoid.

    Features:A semi-synthetic derivative of a natural taxoid.

  • Epothilone B (EPO906, Patupilone)

    Epothilone B (EPO906, Patupilone) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Recently Viewed Items

Tags: buy Vincristine sulfate | Vincristine sulfate ic50 | Vincristine sulfate price | Vincristine sulfate cost | Vincristine sulfate solubility dmso | Vincristine sulfate purchase | Vincristine sulfate manufacturer | Vincristine sulfate research buy | Vincristine sulfate order | Vincristine sulfate mouse | Vincristine sulfate chemical structure | Vincristine sulfate mw | Vincristine sulfate molecular weight | Vincristine sulfate datasheet | Vincristine sulfate supplier | Vincristine sulfate in vitro | Vincristine sulfate cell line | Vincristine sulfate concentration | Vincristine sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us